Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Roland Wolf

Showing results (31-40 of 159) with videos related to

Pageof 16
Sort By:
Oncology Research|April 12, 2003
Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidaseJolanta Pawłowska, Jolanta Tarasiuk, C Roland Wolf, et al.
Drug Metabolism Reviews|June 12, 2009
Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interiorLesley A Stanley, Brian C Horsburgh, Jillian Ross, et al.
Drug Metabolism Reviews|August 1, 2006
PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicityLesley A Stanley, Brian C Horsburgh, Jillian Ross, et al.
F1000Research|July 10, 2023
Potential of <i>in vivo</i> stress reporter models to reduce animal use and provide mechanistic insights in toxicity studiesFrancisco Iñesta Vaquera, Febe Ferro, Michael McMahon, et al.
The Biochemical Journal|February 19, 2005
Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null miceXiu Jun Wang, Mark Chamberlain, Olga Vassieva, et al.
Anti-Cancer Drugs|December 30, 2011
Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cellsDorota Kostrzewa-Nowak, Bohdan Bieg, Mark J I Paine, et al.
Molecular Pharmacology|February 7, 2015
Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivoColin J Henderson, Lesley A McLaughlin, Nico Scheer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 25, 2012
Generation and characterization of a novel multidrug resistance protein 2 humanized mouse lineNico Scheer, Praveen Balimane, Michael D Hayward, et al.
Molecular Pharmacology|May 1, 2010
Deletion of microsomal cytochrome b5 profoundly affects hepatic and extrahepatic drug metabolismLesley A McLaughlin, Sebastien Ronseaux, Robert D Finn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 2011
Characterization of a human keratinocyte HaCaT cell line model to study the regulation of CYP2S1Alison D McNeilly, Julie A Woods, Sally H Ibbotson, et al.
Pageof 16

Showing results (31-40 of 159) with videos related to

Sort By:
Pageof 16
Oncology Research|April 12, 2003
Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidaseJolanta Pawłowska, Jolanta Tarasiuk, C Roland Wolf, et al.
Drug Metabolism Reviews|June 12, 2009
Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interiorLesley A Stanley, Brian C Horsburgh, Jillian Ross, et al.
Drug Metabolism Reviews|August 1, 2006
PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicityLesley A Stanley, Brian C Horsburgh, Jillian Ross, et al.
F1000Research|July 10, 2023
Potential of <i>in vivo</i> stress reporter models to reduce animal use and provide mechanistic insights in toxicity studiesFrancisco Iñesta Vaquera, Febe Ferro, Michael McMahon, et al.
The Biochemical Journal|February 19, 2005
Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null miceXiu Jun Wang, Mark Chamberlain, Olga Vassieva, et al.
Anti-Cancer Drugs|December 30, 2011
Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cellsDorota Kostrzewa-Nowak, Bohdan Bieg, Mark J I Paine, et al.
Molecular Pharmacology|February 7, 2015
Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivoColin J Henderson, Lesley A McLaughlin, Nico Scheer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 25, 2012
Generation and characterization of a novel multidrug resistance protein 2 humanized mouse lineNico Scheer, Praveen Balimane, Michael D Hayward, et al.
Molecular Pharmacology|May 1, 2010
Deletion of microsomal cytochrome b5 profoundly affects hepatic and extrahepatic drug metabolismLesley A McLaughlin, Sebastien Ronseaux, Robert D Finn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 2011
Characterization of a human keratinocyte HaCaT cell line model to study the regulation of CYP2S1Alison D McNeilly, Julie A Woods, Sally H Ibbotson, et al.
Pageof 16